Secondary Prevention of atherotrobmotic eventsClopidogrel is indicated in :• Adult Patients suffering from myocardial infarction (from a few days until less than 35 days), ischaemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease.• Adult Patients suffering from Acute Coronary Syndrome- Non-ST segment elevation acute coronary syndrome (unstable angina/non-Q-wave myocardial infarction (MI)), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (ASA). – ST segment elevation acute myocardial infarction, in combination with ASA in medically treated patients eligible for thrombolytic therapyPrevention of atherotrobmotic and thromboembolic events in atrial fibrillation: In adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for the treatment with Vitamin K antagonists (VKA) Anti-Thrombin or Anti Factor Xa, and who have a low bleeding risk, clopidogrel is indicated in combination with ASA for the prevention of atherothrombotic and thromboembolic events, including stroke.
By using this service, I authorize Athenascripts.com or its agents to receive my prescription, supply medications from a pharmacy, and send them to me. I agree to waive my right to a pharmacist consultation (except for medications requiring pharmacological guidance) and understand that I can consult a pharmacist via email or phone.
Additionally, I consent to receive marketing messages from Athenascripts.com at the phone number provided. I understand I will receive notification messages, data rates may apply, and I can reply STOP to opt out.
Be the first to review “Plavix® 75mg”